The objective of this Phase III double-blind parallelgroup controlled study was to examine the superiority of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with essential hypertension whose systolic blood pressure (SBP) had not reached the therapeutic target levels (o130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily. This study consisted of the 1-week prescreening, 8-week screening and 8-week double-blind periods. Changes in trough SBP from baseline at week 8 of the double-blind period (week 8) were À7.0 mm Hg and À13.7 mm Hg in the amlodipine 5 and 10 mg groups, respectively; a significant difference (Po0.001) was found between the two groups. Changes in trough diastolic blood pressure (DBP) from baseline at week 8 were À2.7 mm Hg and À6.8 mm Hg in the amlodipine 5 and 10 mg groups, respectively, with a significant difference (Po0.001) between the two groups. At week 8, responder rates were 28.5 and 44.0% in the amlodipine 5 mg and 10 mg groups, respectively, with a significant difference (P ¼ 0.002) between the two groups. The amlodipine 10 mg group showed no significant difference in the incidences of adverse events against the amlodipine 5 mg group. The incidence of mild peripheral oedema was 4% only in the amlodipine 10 mg group. In conclusion, amlodipineIntroduction Amlodipine, a dihydropyridine calcium antagonist, shows both vasodilating activity and vasodilationinduced antihypertensive activity. In foreign countries, the usual initial antihypertensive oral dose of NORVASC is 5 mg once daily with a maximum dose of 10 mg once daily. In Japan, however, usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Different measures, for example, uptitration, combination with other drug(s) and switching to other drug(s), may be taken for patients whose blood pressures (BPs) are insufficiently controlled at the usual doses of antihypertensive drugs. It is very important to select an antihypertensive drug that is most suitable for the patient by considering advantages of administering the drug alone or in combination with other drug(s), as well as patient condition. Amlodipine is the most frequently prescribed drug among antihypertensive drugs available in Japan. However, no foreign study has specifically examined the incremental effects of amlodipine uptitration to 10 mg once daily on patients whose BPs did not reach the therapeutic target levels (o130-140/80-90 mm Hg; hereafter referred to as the target levels) by the usual dose of amlodipine 5 mg once daily. Several Western studies have shown a greater BP-lowering effect with the 10 mg once daily dose than with the 5 mg once daily dose. 1 Many Japanese outpatients with essential hypertension, whose systolic BP (SBP) is X140 mm Hg in consecutively measured values of SBP, did not reach the target levels. 2 In Japanese patients with essential hypertension who had insufficiently responded to treatment with amlodipine 5 mg once daily, therefore, we conducted this Phase-III, double-blind, amlodipine 5 mg once dailycontrolled study of amlodipine 10 mg once daily to examine the change in trough SBP from baseline at week 8 of the double-blind period (week 8). The objective of this clinical study was to examine the antihypertensive superiority of amlodipine 10 mg once daily to amlodipine 5 mg once daily.
Materials and methods

Study design
Between 6 January 2007 and 20 October 2007, this Phase III, multicentre, collaborative, double-blind, parallel-group, amlodipine 5 mg once daily-controlled study of amlodipine 10 mg once daily was conducted in subjects with essential hypertension aged 20-79 years at 24 medical institutions in Japan. This study consisted of the 1-week prescreening, 8-week screening and 8-week double-blind periods. Amlodipine 5 mg was administered orally once daily in a single-blind fashion during the screening period. At visit 5 (week 0: baseline), subjects were randomly assigned to receive amlodipine 5 mg or 10 mg during the double-blind period (Figure 1) .
Before its conduct, this clinical study was approved by the Institutional Review Board at each study site. Written informed consent for enrolment in the study was obtained from all subjects or their legally acceptable representatives.
Method of administration Prescreening period. Patients received amlodipine or another antihypertensive drug for 1 week.
Screening period. The administration of antihypertensive drugs other than amlodipine was prohibited. One 5-mg tablet of amlodipine besilate and one placebo of the amlodipine besilate 5-mg tablet were administered orally once daily, after every breakfast, for 8 weeks.
Double-blind period. All enrolled patients only received amlodipine besilate or placebo; such as, one 5-mg tablet of amlodipine besilate and one placebo of the amlodipine besilate 5-mg tablet, or two 5-mg tablets of amlodipine besilate were administered orally once daily, after every breakfast, for 8 weeks.
Diagnostic criteria and key criteria for inclusion At visits 1 (onset of the prescreening period) and 2 (onset of the screening period), 356 subjects who had essential hypertension were enrolled in this study; no regard was given to gender. Inclusion criteria were as follows: X160 mm Hg in SBP or X100 mm Hg in diastolic BP (DBP) when not taking any antihypertensive drug; X140 mm Hg in SBP or X90 mm Hg in DBP when taking an antihypertensive drug. At visits 4 (week À2) and 5 (week 0: Phase III study of amlodipine 10 mg once daily T Fujiwara et al baseline), furthermore, this clinical study enrolled those subjects whose compliance rate throughout the screening period was X80% and who insufficiently responded to amlodipine 5 mg once daily. The criterion for poor response was defined as X140 mm Hg in consecutively measured values of SBP at visits 4 and 5.
Evaluation of efficacy Measurement of BP. At visits 1 (prescreening) to 9 (week 8), trough BPs were measured three times in total after at least a 5-min rest in the sitting position.
The mean values of BPs at the second and third measurements were employed. All the measurements were conducted with a digital automatic sphygmomanometer (HEM-1010; Omron, Tokyo, Japan; Figure 1 ).
Primary endpoint. Change in trough SBP from baseline (the value at the onset of the double-blind period) at week 8.
Secondary endpoints 
Laboratory tests
The following laboratory tests were conducted at visits 1 (prescreening), 5 (week 0; baseline), 7 (week 4) and 9 (week 8 or at discontinuation): hematology-WBC count, differential WBC count (neutrophils, eosinophils, basophils, lymphocytes and monocytes), RBC count, hematocrit, hemoglobin and platelet count; blood chemistry-total bilirubin, direct bilirubin, AST, ALT, LDH, ALP, CK, g-GTP, total protein, albumin, total cholesterol, uric acid, BUN, creatinine, Na, K, Cl, fasting blood glucose, HbA 1c (only visit 1); serum pregnancy test-in women of childbearing potential only at visit 1 (at the onset of the prescreening period) and visit 9 (at week 8 or discontinuation); and urinalysis-protein, occult blood and glucose.
All the measurements were performed at Mitsubishi Kagaku Bio-Clinical Laboratories, Inc.
Evaluation of pharmacokinetics
Plasma amlodipine concentrations (trough concentrations in a steady state) were measured by gas chromatography using an electron-capturing device on visits 5 (week 0), 7 (week 4) and 9 (week 8) at PPD, where measurement devices were calibrated before each measurement to precisely determine intra-and interindividual variations. At the time of each blood collection, 7 ml of blood collected into the heparin sodium-containing test tube were mixed with an anticoagulant by gentle agitation of the tube. Subsequently, the tube was centrifuged (1700 g, 10 min, room temperature) to rapidly collect the plasma (about X3 ml) into the screw-capped sample tube. The plasma obtained was stored at about À20 1C. The assay limit for amlodipine was set to 0.2 ng ml À1 .
Evaluation of safety
The safety of amlodipine 5 mg and 10 mg once daily was assessed through adverse events, laboratory values, body weight, 12-lead ECG and pulse rate.
Statistical procedures
Analysis of efficacy. The primary endpoint was the change in trough SBP from baseline at week 8.
To fulfil the primary objective of this clinical study-examination of the superiority of the amlodipine 10 mg group to the amlodipine 5 mg group, the hypothesis that there is no significant difference between the two groups (null hypothesis) was tested against the hypothesis that the amlodipine 10 mg group is superior to the amlodipine 5 mg group (alternative hypothesis). Furthermore, a value of Po0.05, two-tailed, was considered statistically significant. To conduct the test, an analysis of covariance (ANCOVA) model was used considering trough SBP at baseline, body weight and age as covariates, and administration group and study site as factors. Furthermore, the ANCOVA model was used to estimate the mean value in each group, intergroup difference in mean value and each confidence interval. Confidence interval was set to 0.95 in confidence coefficient (two-tailed).
SAS (release 8.2; SAS Inc., San Francisco, CA, USA) was used to perform all statistical analyses.
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Results
Subject background
Of the 365 subjects who received amlodipine 5 mg during the screening period, 305 who completed the screening period, who met the inclusion criteria for advance to the double-blind period, and who did not fall under the exclusion criteria were randomly assigned to receive amlodipine 5 mg (154 subjects) or 10 mg (151 subjects) during the double-blind period. Sixty subjects failed to advance to the double-blind period because they did not meet the inclusion criteria. Amlodipine was discontinued for five subjects each in the two groups; consequently, about 97% of subjects completed the study. Demographic characteristics of subjects who advanced to the double-blind phase are shown in Table 1 . No significant difference was found with respect to all parameters examined in this study.
The details of 305 subjects who advanced to the double-blind period were as follows in the amlodipine 5 and 10 mg groups, respectively: for mean age, 60.5 years and 60.9 years; for the male-to-female ratio, 83:71 and 92:59; for mean body weight, 66.2 kg and 66.9 kg; for mean body mass index, 25.5 and 25.4 kg/m 2 ; and for mean height, 160.8 cm and 161.9 cm. Except the fact that the proportion of women was slightly lower in the amlodipine 10 mg group, demographic characteristics of subjects who were assigned to the amlodipine 5 mg and 10 mg groups were comparable between the two groups. All subjects had hypertension, and the mean durations of disease were 9.1 years and 8.5 years in the amlodipine 5 mg and 10 mg groups, respectively.
Of the subjects, 60 (39.0%) in the amlodipine 5 mg group and 53 (35.1%) in the amlodipine 10 mg group had histories (for example, hyperlipidemia and diabetes mellitus), whereas 137 (89.0%) in the amlodipine 5 mg group and 140 (92.7%) of the amlodipine 10 mg group had complications. Histories and complications were comparable between the two groups, and about half of subjects were complicated by hyperlipidemia (Table 2) .
Before the onset of this clinical study, almost all subjects who advanced to the double-blind period had undergone some treatment; 153 (99.4%) in the amlodipine 5 mg group and 147 (97.4%) in the amlodipine 10 mg group had undergone pharmacotherapies, and 7 (4.5%) in the amlodipine 5 mg group and 8 (5.3%) in the amlodipine 10 mg group had undergone non-pharmacotherapies. Combined pharmacotherapies before the onset of amlodipine administration and during the double-blind period were almost equivalent between the two groups ( Table 3) .
During the double-blind period, pharmacotherapy was combined for 122 subjects (79.2%) in the amlodipine 5 mg group and for 112 (74.2%) in the amlodipine 10 mg group; non-pharmacotherapy was combined for 17 subjects (11.0%) in the amlodipine 5 mg group and for 16 (10.6%) in the amlodipine 10 mg group. The main drugs that were used in combination during the double-blind period were as follows: pravastatin sodium (20 subjects), allopurinol (14 subjects), aspirin (12 subjects), Chinese medicine (9 subjects) and ketoprofen (8 subjects) in the amlodipine 5 mg group; pravastatin sodium (16 subjects), loxoprofen sodium hydrate (12 subjects), allopurinol (11 subjects), ambroxol hydrochloride Abbreviations: BMI, body mass index; N, number of subjects evaluated. BMI ¼ body weight (kg)/height (m 2 ). All subjects enrolled in this study were Japanese outpatients.
Phase III study of amlodipine 10 mg once daily T Fujiwara et al (8 subjects) and diclofenac sodium (8 subjects). The contents of combined pharmacotherapy during the double-blind period were almost comparable between the two groups (Table 3) .
Efficacy
Primary endpoint. In the analysis set for primary endpoint-full analysis set (FAS), changes (least square means) in trough SBP from baseline at week 8 were À7.0 and À13.7 mm Hg in the amlodipine 5 mg and 10 mg groups, respectively. Therefore, a statistically significant difference (Po0.001) was found between the two groups (Table 4 ; Figure 2 ). This result validated the superiority of the amlodipine 10 mg group to the amlodipine 5 mg group with respect to changes in trough SBP from baseline at week 8. The analysis set for secondary endpoint, per protocol set, also afforded results comparable to those of the FAS, thus verifying the stability of the FAS analysis.
Secondary endpoints. Changes (least square means) in trough DBP from baseline in the FAS at week 8 were À2.7 and À6.8 mm Hg in the amlodipine 5 mg and 10 mg groups, respectively. Therefore, a statistically significant difference (Po0.001) was found between the two groups ( Table 4 ; Figure 2 ).
Responder rates
The amlodipine 10 mg group showed a significantly higher responder rate (44.0%, 66/150 subjects; Po0.002; odd ratio, 2.33; 95% CI, 1.36-3.99) against the amlodipine 5 mg group (28.5%, 43/151 subjects).
Stratified analyses
The trough SBP values were stratified and analysed by age, body weight and gender in the FAS. Consequently, a comparison among the strata revealed biased differences between the two groups. All subgroups showed changes that were greater in the amlodipine 10 mg group than in the amlodipine 5 mg group, which coincided with the results of the primary analysis (Table 5) .
Pharmacokinetics
Plasma trough concentrations of amlodipine (geometric means) at week 8 were as follows: 7.03 ng ml À1 . in the amlodipine 5 mg group; and 16.9 ng ml À1 in the amlodipine 10 mg group. As plasma trough concentrations of amlodipine were almost twofold the values in the amlodipine 5 mg group and at baseline, plasma amlodipine concentrations increased in response to doses.
Safety
The incidences of adverse events, whose causality with amlodipine was undeniable (adverse reactions) and that were observed during the double-blind period, are summarized in Table 6 .
The number of adverse reactions of amlodipine were as follows: 8 episodes in 6 (3.9%) cases among 154 subjects in the amlodipine 5 mg group; and 18 episodes in 15 (9.9%) cases among 151 subjects in the amlodipine 10 mg group. Adverse reactions about which concern was elicited by the uptitration of amlodipine from 5 to 10 mg daily, that is, hot flushes, vertigo/dizziness, headache/dull headache, palpitation, excessive drop in BP, oedema and peripheral oedema, were examined. Consequently, The number of subjects who were entered in the database as having received amlodipine besilate and the number of those as having received amlodipine are summed up. b Combination cold remedy (mixture).
Phase III study of amlodipine 10 mg once daily T Fujiwara et al any adverse events categorized to headache and vascular disorders, for example, hot flushes, were not observed. Furthermore, tachycardia and decreased BP were not reported as adverse events. Among adverse events that are possibly associated with an excessive drop in BP, for example, vertigo, dizziness was not observed in the amlodipine 10 mg group. None in the amlodipine 10 mg group showed oedema. Five cases (3.3%) of peripheral oedema developed only in the amlodipine 10 mg group.
The administration of amlodipine was discontinued due to adverse events during the double-blind period for one subject each in the amlodipine 5 mg group and the amlodipine 10 mg group.
Discussion
Different clinical studies have verified the efficacy of amlodipine given by uptitration to 10 mg once daily. In large-scale clinical studies in patients with hypertension at low to high risks for cardiovascular events-ALLHAT, 3 VALUE 4 and ASCOT, 5 amlodipine given by uptitration to 10 mg once daily has been reported to allow the secure control of BP and to suppress cardiovascular events. In a variety of studies in Asian populations; furthermore, amlodipine 5 to 10 mg once daily has provided a sufficient antihypertensive effect on and good tolerability for hypertensive patients. [6] [7] [8] [9] [10] [11] [12] [13] [14] In addition, PRAISE, 15 Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; N: number of subjects evaluated; SBP, systolic blood pressure. Baseline: Onset of the double-blind period (visit 5). The P value and the least square mean were calculated using an ANCOVA model that considered trough SBP and DBP at baseline, body weight and age as covariates, and administration group and study site as factors. Phase III study of amlodipine 10 mg once daily T Fujiwara et al that was conducted in patients with severe chronic heart failure, verified that amlodipine 5 to 10 mg once daily does not adversely affect them. On the other hand, elderly patients with systolic hypertension in whom the aorta has become sclerotic present the already decreased activity of the renin-angiotensin system; therefore, angiotensin receptor blockers and b-blockers are less prone to exert their antihypertensive effect. Calcium antagonists have the following advantages as antihypertensive agents: maintenance of cerebral, coronary, renal and peripheral circulations at good levels despite showing a secure antihypertensive effect; absence of adverse effects on glucose and lipid metabolism. Moreover, calcium antagonists have been found to possess blocking activity on arteriosclerosis progression. 16 Approximately 60% of patients with essential hypertension who were undergoing treatment with antihypertensive drugs including amlodipine failed to achieve the target BP levels that were stipulated by the 2000 JSH guidelines. 2 As guidelines for the management of hypertension in the United States, 17 Europe 18 and Japan established the more strict control of BP in hypertensive patients, greater needs to demonstrate evidence for uptitrating amlodipine from 5 to 10 mg once daily were generated.
In response to the above needs, a number of clinical trials of amlodipine 10 mg once daily in Western countries were conducted to examine its efficacy and safety in hypertensive patients. Consequently, amlodipine was demonstrated to be effective and safe at the dose in those patients. To date, however, the incremental benefit of uptitration from 5 mg once daily to 10 mg once daily has little been examined in Japanese patients with essential hypertension.
Therefore, we conducted this study to examine the above superiority in patient with essential hypertension whose SBP had not reached the target levels when treated with amlodipine 5 mg once daily. Consequently, amlodipine uptitration from 5 to 10 mg once daily significantly improved the antihypertensive effect of the drug on both SBP and DBP. Furthermore, the rate of target level achievement was 40.7% in this study. Stratified analyses by age, body weight and gender revealed the antihypertension-enhancing effect of uptitration to 10 mg once daily. A previous clinical study reported that the young to middle-aged patient group presents greater antihypertensive responsiveness as compared with the elderly patient group. 19 Except the slightly increased incidence of peripheral oedema, amlodipine uptitration to 10 mg once daily indicated no increase in the incidences of adverse reactions of particular concern in overall Abbreviation: N, number of subjects evaluated. Baseline: Onset of the double-blind period (visit 5).
The P value and the least square mean were calculated using an ANCOVA model that considered trough DBP at baseline, body weight and age as covariates, and administration group and study site as factors. Abbreviation: N, total number of subjects evaluated.
Phase III study of amlodipine 10 mg once daily T Fujiwara et al and stratified tabulations. Therefore, the good tolerability of amlodipine 10 mg once daily in subjects was thus verified. Regarding safety, oedema-especially peripheral oedema about which concern was elicited from the beginning of this study-developed only in the amlodipine 10 mg group. Although we considered it necessary to provide medical institutions with appropriate information on the incidence of peripheral oedema that developed after uptitration to 10 mg once daily, its incidence was about 4%. All cases of peripheral oedema were mild and required no particular action. This study verified the usefulness of amlodipine 10 mg once daily for Japanese patients who insufficiently responded to amlodipine 5 mg once daily for 8 weeks. Amlodipine 10 mg once daily exhibited favourable antihypertensive activity regardless of categories of age and gender. The pathogenesis of oedema is presumed as follows: the vasodilating activity of a calcium antagonist is more potent in peripheral arteries than in veins, resulting in the failure of venulae to dilate in proportion as arteriolar dilation and leading to an increase in capillary inner pressure. Namely, we consider that peripheral oedema developed due to a difference in the vasodilating activity of amlodipine on arterioles and venulae, and not due to an increase in whole body fluid volume. The incidences of peripheral oedema have been reported to be higher in hypertensive patients receiving short-acting calcium channel blockers of first and second generations than in those receiving long-acting calcium antagonists. 20, 21 However, the incidence rates of the adverse reactions provoked by amlodipine of longacting calcium antagonist are not so high compared with short-acting calcium antagonist. In fact, the incidence rate in this study was low. Furthermore, the overall incidences of adverse reactions of amlodipine in this study were low. This fact is not contradictory to a large-scaled randomized clinical trial of candesartan and amlodipine in Japanese patients with essential hypertension that reported the incidences of individual adverse reactions of candesartan and amlodipine which were as low as o 3%. 22 The amlodipine 10 mg group showed increased pulse rate. Because of its transience, however, the adverse event was considered attributable to the activity of the sympathetic nervous system that was enhanced by the antihypertensive effect of amlodipine.
Based on the above, the therapeutic benefit of amlodipine uptitration to 10 mg once daily for patients who insufficiently responded to amlodipine 5 mg once daily is considered to outweigh the risk of developing adverse events. Therefore, we regard it meaningful to uptitrate amlodipine from 5 mg to 10 mg once daily as a therapeutic option among antihypertensive treatments to fully control BP in patients whose BPs did not reach the target levels when treated with amlodipine 5 mg. 
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What is known about the topic K Guidelines for the management of hypertension in the United States, Europe and Japan established the more strict control of blood pressure in hypertensive patients. K Greater needs to demonstrate evidence for uptitrating amlodipine from 5 mg to 10 mg once daily were generated. K A number of clinical trials of amlodipine 10 mg once daily in Western countries were conducted to examine its efficacy and safety in hypertensive patients. Consequently, amlodipine was demonstrated to be effective and safe at the dose in those patients. To date, however, the incremental benefit of uptitration from 5 mg once daily to 10 mg once daily has been little examined in Japanese patients with essential hypertension.
What this study adds K We conducted this study to examine the superiority of amlodipine 10 mg once daily in Japanese patient with essential hypertension whose SBP had not reached the target levels (130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily. K This study showed that the therapeutic benefit of amlodipine uptitration to 10 mg once daily for the above patients outweighs the risk of developing adverse events, indicating the uptitration of amlodipine from 5 mg to 10 mg once daily is a therapeutic option among antihypertensive treatments.
